Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, 4-Week, Double-Blind, Proof-of-Concept Efficacy and Safety Study of ACP-196 Versus Placebo in Subjects With Active Rheumatoid Arthritis on Background Methotrexate

NCT02387762 is registered in ClinicalTrials.gov with Acerta Pharma BV as lead sponsor.

NCT NCT02387762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02387762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, 4-Week, Double-Blind, Proof-of-Concept Efficacy and Safety Study of ACP-196 Versus Placebo in Subjects With Active Rheumatoid Arthritis on Background Methotrexate
Lead sponsor
Acerta Pharma BV
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2015
Completion date
June 30, 2016
Enrollment
31 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis